

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3454305

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT	07/07/2015

**RECEIVING PARTY DATA**

<b>Name:</b>	CALIXA THERAPEUTICS, INC.
<b>Street Address:</b>	65 HAYDEN AVENUE
<b>City:</b>	LEXINGTON
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02421
<b>Name:</b>	ADOLOR CORPORATION
<b>Street Address:</b>	700 PENNSYLVANIA DRIVE
<b>City:</b>	EXTON
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19341
<b>Name:</b>	CUBIST PHARMACEUTICALS, INC.
<b>Street Address:</b>	65 HAYDEN AVENUE
<b>City:</b>	LEXINGTON
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02421

**PROPERTY NUMBERS Total: 104**

Property Type	Number
Patent Number:	5565486
Patent Number:	5824485
Patent Number:	5783431
Patent Number:	6242211
Patent Number:	5726195
Patent Number:	6221640
Patent Number:	6468967
Patent Number:	6852689
Patent Number:	6911525
Patent Number:	7335725

PATENT

<b>Property Type</b>	<b>Number</b>
Patent Number:	7408025
Patent Number:	6794490
Patent Number:	7262268
Patent Number:	6846625
Patent Number:	6475726
Patent Number:	6436694
Patent Number:	6319898
Patent Number:	6297007
Patent Number:	6153645
Patent Number:	6132984
Patent Number:	4885243
Patent Number:	4537717
Application Number:	12641465
Application Number:	11912833
Application Number:	13481009
Application Number:	61618119
Application Number:	61618127
Application Number:	61618131
Application Number:	61618136
Application Number:	61644974
Application Number:	61645301
Application Number:	61681506
Application Number:	61698241
Application Number:	61698256
Application Number:	08612680
Application Number:	08796078
Application Number:	09436057
Application Number:	10066909
Application Number:	10455687
Patent Number:	6303611
Patent Number:	6239154
Patent Number:	5811078
Patent Number:	5798093
Patent Number:	5855907
Patent Number:	5849762
Patent Number:	5869521
Patent Number:	6156769
Patent Number:	6469030

<b>Property Type</b>	<b>Number</b>
Patent Number:	7696220
Patent Number:	6451806
Patent Number:	6630462
Patent Number:	6794510
Patent Number:	7091354
Patent Number:	7381721
Patent Number:	7884102
Patent Number:	6992193
Patent Number:	6992090
Patent Number:	7820827
Patent Number:	8288546
Patent Number:	7338962
Patent Number:	7638527
Patent Number:	7906646
Patent Number:	8071611
Patent Number:	7160902
Patent Number:	7087749
Patent Number:	7767814
Patent Number:	7700626
Patent Number:	7034051
Patent Number:	7671052
Patent Number:	7598261
Patent Number:	8022060
Patent Number:	7914776
Patent Number:	7538110
Patent Number:	8278323
Patent Number:	7544676
Patent Number:	7576207
Patent Number:	7829576
Patent Number:	8112290
Patent Number:	6573282
Patent Number:	5994372
Patent Number:	5888494
Application Number:	13477742
Application Number:	13479622
Application Number:	13427744
Application Number:	13252982
Application Number:	13097940

Property Type	Number
Application Number:	12388950
Application Number:	12107742
Application Number:	10999054
Application Number:	13007854
Application Number:	13274616
Application Number:	11582681
Application Number:	11851995
Application Number:	12388903
Application Number:	13648153
Application Number:	13541628
Application Number:	12795095
Application Number:	12884985
Application Number:	13571288
Application Number:	61681571
Application Number:	61657386
Application Number:	13607138
Application Number:	13628742
Application Number:	61706399

**CORRESPONDENCE DATA**

**Fax Number:** (212)246-8959

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2127083460

**Email:** slebson@ladas.com

**Correspondent Name:** LADAS & PARRY LLP

**Address Line 1:** 1040 AVENUE OF THE AMERICAS

**Address Line 4:** NEW YORK, NEW YORK 10018

**ATTORNEY DOCKET NUMBER:** NPA1150325:753

**NAME OF SUBMITTER:** SCOTT J. LEBSON

**SIGNATURE:** /sjl/

**DATE SIGNED:** 07/24/2015

**Total Attachments: 11**

source=ReleaseofSecurityInterest#page1.tif

source=ReleaseofSecurityInterest#page2.tif

source=ReleaseofSecurityInterest#page3.tif

source=ReleaseofSecurityInterest#page4.tif

source=ReleaseofSecurityInterest#page5.tif

source=ReleaseofSecurityInterest#page6.tif

source=ReleaseofSecurityInterest#page7.tif

source=ReleaseofSecurityInterest#page8.tif  
source=ReleaseofSecurityInterest#page9.tif  
source=ReleaseofSecurityInterest#page10.tif  
source=ReleaseofSecurityInterest#page11.tif

TERMINATION OF SECURITY INTEREST IN PATENTS AND PATENT APPLICATIONS

This Termination of Security Interest in Patents and Patent Applications is made as of July 7, 2015 by Royal Bank of Canada, as Administrative Agent (the "**Secured Party**").

WHEREAS, (i) Merck Sharp & Dohme Corp. (the "**Company**") owns the indicated patents and patent applications listed on Exhibit A attached hereto ("**Listed MSD Patents and Patent Applications**") as assignee from each of Cubist Pharmaceuticals LLC (formerly known as Cubist Pharmaceuticals, Inc.) (the "**Borrower**"), Calixa Therapeutics Inc. ("**Calixa**") and Adolor Corporation ("**Adolor**") and, together with the Borrower, Cubist Pharmaceutical Holdings, Inc., Cubist Pharmaceuticals U.S. and Calixa, the "**Grantors**", and (ii) the Borrower owns the indicated patents and patent applications listed on Exhibit B attached hereto ("**Listed Cubist Patents and Patent Applications**") and together with the Listed MSD Patents and Patent Applications, the "**Listed Patents and Patent Applications**") which patents and patent applications are registered in the United States Patent and Trademark Office (the "**Office**"); and

WHEREAS, each Grantor has granted to the Secured Party, as Administrative Agent (as defined in the Patent Security Agreement defined below) a security interest in and lien upon certain patents and patent applications, including but not limited to the Listed Patents and Patent Applications, the registrations thereof and related rights all as described in that certain Patent Security Agreement dated as of November 20, 2012 and recorded on November 20, 2012 with the Office at Reel 029339, Frame 0669 ("**Patent Security Agreement**"); and

WHEREAS, the Secured Party has at the Borrower's request agreed to release its security interest in all of the Company's and the Borrower's, as applicable, patents and patent applications, including the Listed Patents and Patent Applications, and the registrations thereof and the related rights therein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Secured Party hereby releases and reassigns its security interest in all of the Company's and the Borrower's, as applicable, patents and patent applications previously granted to the Secured Party including the Listed Patents and Patent Applications, and the registrations thereof and the related rights therein and to any other rights it might have arising out of the Patent Security Agreement; and authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

ROYAL BANK OF CANADA, as Secured  
Party


By:   
Name: Ann Hurley  
Title: Manager, Agency

EXHIBIT A  
TO  
RELEASE OF SECURITY INTEREST IN PATENTS AND PATENT APPLICATIONS

**PATENTS AND PATENT APPLICATIONS (MSD)**

<b>LOAN PARTY</b>	<b>PATENT TITLE</b>	<b>APPLICATION NUMBER</b>	<b>PATENT NUMBER</b>	<b>ISSUE DATE</b>
Cubist Pharmaceuticals, Inc.	Sesquiterpenes, Their Preparation and Their Use as Inhibitors Acting on the Gaba-Benzodiazepine Receptor	08/464,737	5,565,486	10/15/96
Cubist Pharmaceuticals, Inc.	Methods for Generating and Screening Novel Metabolic Pathways	08/639,255	5,824,485	10/20/98
Cubist Pharmaceuticals, Inc.	Methods for Generating and Screening Novel Metabolic Pathways	08/738,944	5,783,431	07/21/98
Cubist Pharmaceuticals, Inc.	Methods for Generating and Screening Novel Metabolic Pathways	09/263,352	6,242,211	06/05/01
Cubist Pharmaceuticals, Inc.	Aminoacyl Adenylate Mimics as Novel Antimicrobial and Antiparasitic Agents	08/683,809	5,726,195	03/10/98
Cubist Pharmaceuticals, Inc.	Enterococcal Aminoacyl-tRNA Synthetase Proteins, Nucleic Acids and Strains Comprising Same	08/855,910	6,221,640	04/24/01
Cubist Pharmaceuticals, Inc.	Methods for Administration of Antibiotics	09/406,568	6,468,967	10/22/02
Cubist Pharmaceuticals, Inc.	Methods for Administration of Antibiotics	10/082,544	6,852,689	02/08/05
Cubist Pharmaceuticals, Inc.	Novel Lipopeptides as Antibacterial Agents	09/738,742	6,911,525	06/28/05
Cubist Pharmaceuticals, Inc.	Novel Lipopeptides as Antibacterial Agents	11/121,851	7,335,725	02/26/08
Cubist Pharmaceuticals, Inc.	Novel Lipopeptides as Antibacterial Agents	09/737,908	7,408,025	08/05/08



LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Cubist Pharmaceuticals, Inc.	Novel Lipopeptides as Antibacterial Agents	09/739,535	6,794,490	09/21/04
Cubist Pharmaceuticals, Inc.	Lipopeptide Stereoisomers, Methods for Preparing Same, and Useful Intermediates	10/213,218	7,262,268	08/28/07
Cubist Pharmaceuticals, Inc.	Method for Identifying Validated Target and Assay Combinations for Drug Development	09/227,687	6,846,625	01/25/2005
Cubist Pharmaceuticals, Inc.	Method for Identifying Validated Target and Assay Combinations for Drug Development	09/344,783	6,475,726	11/05/2002
Cubist Pharmaceuticals, Inc.	Regulable Gene Expression in Gram-Positive Bacteria	09/291,874	6,436,694	08/20/2002
Cubist Pharmaceuticals, Inc.	Method for Inhibiting Eukaryotic Protein Kinases	09/174,263	6,319,898	11/20/2001
Cubist Pharmaceuticals, Inc.	Method for Isolation of Biosynthesis Genes for Bioactive Molecules	08/861,774	6,297,007	10/02/2001
Cubist Pharmaceuticals, Inc.	Novel Heterocycles as Antimicrobial Agents	09/393,505	6,153,645	11/28/2000
Cubist Pharmaceuticals, Inc.	Method for Inhibiting Eukaryotic Protein Kinases	09/174,261	6,132,984	10/17/2000
Cubist Pharmaceuticals, Inc.	Process for Producing A-21978C Derivatives	06/773,762	4,885,243	12/05/1989
Cubist Pharmaceuticals, Inc.	Derivatives of A-21978C Cyclic Peptides	06/652,695	4,537,717	08/27/1985
Cubist Pharmaceuticals, Inc.	Novel Antibacterial Agents for the Treatment of Gram Positive Infections	12/641,465	N/A	N/A
Cubist Pharmaceuticals, Inc.	Therapeutic Compositions	11/912,833	N/A	N/A
Cubist Pharmaceuticals, Inc.	CB-183,315 Compositions and Related Methods	13/481,009	N/A	N/A

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Cubist Pharmaceuticals, Inc.	Beta-Lactamase Inhibitors	61/618,119	N/A	N/A
Cubist Pharmaceuticals, Inc.	Beta-Lactamase Inhibitors	61/618,127	N/A	N/A
Cubist Pharmaceuticals, Inc.	Beta-Lactamase Inhibitors	61/618,131	N/A	N/A
Cubist Pharmaceuticals, Inc.	Beta-Lactamase Inhibitors	61/618,136	N/A	N/A
Cubist Pharmaceuticals, Inc.	Cyclic Peptide Compounds and Related Methods, Salts and Compositions	61/644,974	N/A	N/A
Cubist Pharmaceuticals, Inc.	Cyclic Peptide Compounds and Related Methods, Salts and Compositions	61/645,301	N/A	N/A
Cubist Pharmaceuticals, Inc.	Compositions with Increased Stability for Inhibiting Transient Receptor Potential Ion Channel TRPA 1	61/681,506	N/A	N/A
Cubist Pharmaceuticals, Inc.	Cephalosporin Compound	61/698,241	N/A	N/A
Cubist Pharmaceuticals, Inc.	Cephalosporin derivatives and treatment of infections	61/698,256	N/A	N/A
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	08/612,680	5,646,151	07/08/97
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	08/796,078	5,688,955	11/18/97
Adolor Corporation	Kappa Agonist Compounds, Pharmaceutical Formulations and Method of Prevention and Treatment of Pruritus Therewith	09/436,057	6,180,623	01/30/01
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	10/066,909	RE38,133	06/03/03
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	10/455,687	6,960,612	11/01/05

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	09/150,369	6,303,611	10/16/01
Adolor Corporation	Kappa Agonist Compounds and Pharmaceutical Formulations Thereof	09/372,191	6,239,154	05/29/01
Adolor Corporation	Spray Formulations of Antihyperalgesic Opiates and Method of Treating Topical Hyperalgesic Conditions Therewith	08/818,559	5,811,078	09/22/98
Adolor Corporation	Spray Formulations of Antihyperalgesic Opiates and Method of Treating Topical Hyperalgesic Conditions and Pruritus Therewith	08/892,389	5,798,093	08/25/98
Adolor Corporation	Method of Treatment of Migrane	08/828,144	5,855,907	01/05/99
Adolor Corporation	Peripherally Acting Anti-Pruritic Opiates	08/892,194	5,849,762	12/15/98
Adolor Corporation	Kappa Agonists Antipruritic Pharmaceutical Formulations and Method of Treating Pruritus Therewith	09/064,695	5,869,521	02/09/99
Adolor Corporation	Kappa Agonists Antipruritic Pharmaceutical Formulations and Method of Treating Pruritus Therewith	09/488,420	6,156,769	12/05/00
Adolor Corporation	Methods for the Treatment and Prevention of Ileus	09/725,708	6,469,030	10/22/02
Adolor Corporation	Methods for the Treatment or Inhibition of Ileus	10/171,299	7,696,220	04/13/10
Adolor Corporation	Novel Methods and Compositions Involving Opioids and Antagonists Thereof	09/725,661	6,451,806	09/17/02
Adolor Corporation	Delta Agonist Analgesics	10/059,953	6,630,462	10/07/03
Adolor Corporation	Processes for the Preparation of Peripheral Opioid Antagonist Compounds and Intermediates Thereto	10/216,158	6,794,510	09/21/04

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Adolor Corporation	Processes for the Preparation of Peripheral Opioid Antagonist Compounds and Intermediates Thereto	10/888,315	7,091,354	08/15/06
Adolor Corporation	Substituted Piperidine Compounds	10/390,522	7,381,721	06/03/08
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	12/110,915	7,884,102	02/08/11
Adolor Corporation	Sulfonylamino Phenylactamide Derivatives and Methods of Their Use	10/458,135	6,992,193	01/31/06
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	10/462,507	6,992,090	01/31/06
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	11/217,528	7,820,827	10/26/10
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	12/897,824	8,288,546	10/16/12
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	10/957,554	7,338,962	03/04/08
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	11/960,845	7,638,527	12/29/09
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	12/483,781	7,906,646	03/15/11
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	12/718,439	8,071,611	12/06/11
Adolor Corporation	Amids Derivatives and Methods of Their Use	10/713,746	7,160,902	01/09/07
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	10/798,664	7,087,749	08/08/06
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	11/442,075	7,767,814	08/03/10
Adolor Corporation	Compositions Containing Opioid Antagonists	11/143,535	7,700,626	04/20/10
Adolor Corporation	Fused Bicyclic Carboxamide Derivatives and Methods of Their Use	10/651,197	7,034,051	04/25/06
Adolor Corporation	Phenyl Derivatives and Methods of Use	11/242,318	7,671,052	03/02/10

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	11/393,133	7,598,261	10/06/09
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	12/542,302	8,022,060	09/20/11
Adolor Corporation	Solid Dispersions of Opioid Antagonists	11/543,619	7,914,776	03/29/11
Adolor Corporation	Novel Opioid Antagonists	11/552,827	7,538,110	05/26/09
Adolor Corporation	Novel Opioid Antagonists	12/463,814	8,278,323	10/02/12
Adolor Corporation	Sulfamoyl Benzamides and Methods of Their Use	11/558,332	7,544,676	06/09/09
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	11/696,585	7,576,207	08/18/09
Adolor Corporation	Beloxepin and Analogs for the Treatment of Pain	12/750,558	7,829,576	11/09/10
Adolor Corporation	Methods for Delivering a Drug to a Hospital Patient for Short-Term Use While Minimizing Long-Term Use of the Drug	12/467,016	8,112,290	02/07/12
Adolor Corporation	Peripherally Active Anti-Hyperalgesic Opiates	09/374,634	6,573,282	11/13/20 07
Adolor Corporation	Peripherally Active Anti-Hyperalgesic Opiates	08/712,881	5,994,372	11/30/19 99
Adolor Corporation	Film-Forming Compositions of Anihyperalgesic Opiates and Method of Treating Hyperalgesic and Pruritic Conditions Therewith	08/891,924	5,888,494	03/30/19 99
Adolor Corporation	Compositions Containing Opioid Antagonists	13/477,742	N/A	N/A
Adolor Corporation	Novel Opioid Antagonists	13/479,622	N/A	N/A
Adolor Corporation	Compositions of (-) 0-E-10-OH-NT and Methods for Their Synthesis and Use	13/427,744	N/A	N/A
Adolor Corporation	Beloxepin and Analogs for the Treatment of Pain	13/252,982	N/A	N/A
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	13/097,940	N/A	N/A

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	12/483,781	7,906,646	03/15/20 11
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	12/542,302	8,022,060	09/20/20 11
Adolor Corporation	(+)-Beloxepin and Methods for its Synthesis and Use	12/388,950	N/A	N/A
Adolor Corporation	Novel Opioid Antagonists	12/463,814	8,278,323	10/02/20 12
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	12/110,915	7,884,102	02/08/2011
Adolor Corporation	Compositions of (-)-E-10-OH-NT and Methods for their Synthesis and Use	12/107,742	N/A	N/A
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	11/960,845	7,638,527	12/29/2009
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	11/442,075	7,767,814	08/03/2010
Adolor Corporation	Methods of Preventing and Treating Gastrointestinal Dysfunction	10/999,054	N/A	N/A
Adolor Corporation	Novel Processes for the Preparation of Peripheral Opioid Antagonist Compounds and Intermediates Thereto	10/888,315	7,091,354	08/15/20 06
Adolor Corporation	Substituted Piperidine Compounds and Methods of Their Use	13/007,854	N/A	N/A
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	13/274,616	N/A	N/A
Adolor Corporation	Methods of Preventing and Treating Gastrointestinal	10/999,054	N/A	N/A
Adolor Corporation	Compositions Containing Opioid Antagonists	13/477,742	N/A	N/A
Adolor Corporation	Spirocyclic Heterocyclic Derivatives and Methods of Their Use	13/097,940	N/A	N/A
Adolor Corporation	Compositions Containing Opioid Antagonists	11/582,681	N/A	N/A
Adolor Corporation	Novel Opioid Antagonists	13/479,622	N/A	N/A

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Adolor Corporation	Methods for Enhancing Cognitive Function	11/851,995	N/A	N/A
Adolor Corporation	Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use	13/427,744	N/A	N/A
Adolor Corporation	(-)-Beloxepin and Methods for its Synthesis and Use	12/388,903	N/A	N/A
Adolor Corporation	Beloxepin and Analogs for the Treatment of Pain	13/648,153	N/A	N/A
Adolor Corporation	Methods For Delivering a Drug to a Hospital Patient For Short-Term Use While Minimizing Long-Term Use of the Drug	13/541,628	N/A	N/A
Adolor Corporation	Substituted Piperidinylpropanoic Acid Compounds and Methods of Their Use	12/795,095	N/A	N/A
Adolor Corporation	Use of An Opioid Receptor Antagonist For the Treatment or Prevention of Gastrointestinal Tract Disorders	12/884,985	N/A	N/A
Cubist Pharmaceuticals, Inc.	Inhibiting Transient Receptor Potential Ion Channel TRPA1	13/571,288 <sup>1</sup>	N/A	N/A
Cubist Pharmaceuticals, Inc.	Inhibiting Transient Receptor Potential Ion Channel TRPA1	61/681,571 <sup>2</sup>	N/A	N/A
Calixa Therapeutics, Inc.	Methods for Treating Intrapulmonary Infections	61/657,386	N/A	N/A
Calixa Therapeutics, Inc.	Methods for Treating Intrapulmonary Infections	13/607,138	N/A	N/A
Calixa Therapeutics, Inc.	Tazobactam Arginine Compositions	13/628,742	N/A	N/A
Calixa Therapeutics, Inc.	Tazobactam Arginine Antibiotic Compositions	61/706,399	N/A	N/A

<sup>1</sup>. This patent is co-owned with Hydra Biosciences, Inc.

<sup>2</sup>. This patent is co-owned with Hydra Biosciences, Inc.

EXHIBIT B  
TO  
RELEASE OF SECURITY INTEREST IN PATENTS AND PATENT APPLICATIONS

**PATENTS AND PATENT APPLICATIONS (CUBIST)**

LOAN PARTY	PATENT TITLE	APPLICATION NUMBER	PATENT NUMBER	ISSUE DATE
Cubist Pharmaceuticals, Inc.	Methods for Administration of Antibiotics	09/406,568	6,468,967	10/22/02
Cubist Pharmaceuticals, Inc.	Methods for Administration of Antibiotics	10/082,544	6,852,689	02/08/05
Cubist Pharmaceuticals, Inc.	High Purity Lipopeptides, Lipopeptide Micelles and Processes for Preparing Same	09/735,191	6,696,412	02/24/04
Cubist Pharmaceuticals, Inc.	High Purity Lipopeptides	11/739,180	8,058,238	11/15/11
Cubist Pharmaceuticals, Inc.	High Purity Lipopeptides	12/888,233	8,129,342	03/06/12
Cubist Pharmaceuticals, Inc.	Anhydro- and Isomer-a-21978c Cyclic Peptides	09/547,357	RE39,071	04/18/06
Cubist Pharmaceuticals, Inc.	Daptomycin for the Treatment of Biofilm and Catheter Salvage	11/916,089	8,003,673	08/23/11
Cubist Pharmaceuticals, Inc.	High Purity Lipopeptides	13/398,219	N/A	N/A
Cubist Pharmaceuticals, Inc.	High Purity Lipopeptides	13/398,219	N/A	N/A
Cubist Pharmaceuticals, Inc.	Methods for Preparing Purified Lipopeptides	12/198,666	N/A	N/A
Cubist Pharmaceuticals, Inc.	Lipopeptide Compositions and Related Methods	13/511,246	N/A	N/A